Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hoya, Eclipse in aesthetic laser pact:

This article was originally published in Clinica

Executive Summary

Dental and aesthetic medical laser specialist Hoya ConBio has signed an exclusive three-year distribution agreement with Eclipse Medical for its MedLite C series and RevLite lasers. Eclipse will distribute the lasers in Texas, Louisiana, Arkansas and Oklahoma. Hoya (Freemont, California) claims that the MedLite C series and RevLite lasers, which use Q-switched Nd:YAG laser engineering, represent the next generation of laser engineering. This is because they treat patients via the delivery of energy with a "PhotoAcoustic" effect, as opposed to photothermal energy, which other devices use. These lasers are already used widely for tattoo removal, but also have potential uses for wrinkle reduction, acne scars, vascular and pigmented lesions and hair removal.

You may also be interested in...



Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

Wave Of Launches Boosts US Biosimilars Market

A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.

Do Medtechs Know What They Want To Achieve With Digital?

It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations –  and in patient treatment pathways.

Topics

UsernamePublicRestriction

Register

MT049353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel